Register to get unlimited access to our investor forum and all editorial content, including our e-zine and weekly email. Registration is free and only takes a minute.

Latest News - Gavin Lumsden - Page 2

Go for global investment trusts to diversify from Brexit-torn UK

A ‘soft’ Brexit may boost the UK stock market but in case it doesn’t, or if the UK leaves the European Union without a deal, it may be time to have a look again at the many diversified global investment trusts on offer.

Brexit: what to look for in a UK commercial property trust

Brexit fears and high street retail woes have made listed property funds look cheap but potentially attractive for long-term investors.

Deal Or No Deal: where pros are placing their Brexit bets

Where are the best investment trust opportunities in Brexit? Rob St George kicks off exit special edition of Investment Trust Insider’s quarterly ezine.

PRS Reit cuts 2022 dividend target blaming planning delays

Government-backed real estate investment trust cuts long-term dividend target by 8% citing planning delays for slowing the construction of its family rental homes.

Trust Watch: Woodford-backed loan fund offers 11% covered yield

Lots of interesting discount opportunities this week including one high yielding investment trust caught in the shadow of Neil Woodford.

Crystal Amber gains £1m profit on quick Patient Capital trade

Activist investment company backed by Neil Woodford pockets £1 million gain selling stake in fund manager’s Patient Capital investment trust.

Alliance Trust slashes board-room pay in return to roots

The £2.5 billion Dundee-based global fund is cutting the fees it pays senior non-executive directors as it puts finishes four-year retrenchment programme.

Lord Rothschild: UK faces worst political crisis since Suez

Rothschild's RIT Capital Partners succeeded in protecting shareholders from last year's losses but Brexit deadlock and other geopolitical tensions keep veteran investor cautious about year ahead.

Syncona strikes £135m gain as Nightstar bows to Biogen bid

UK’s largest listed life sciences fund benefits from its first takeover after Nightstar Thereapeutics, its third biggest investment, falls to a knockout $877 million (£663 million) cash bid from Biogen of Switzerland.

Trust Watch: ructions, reconstructions & investigations

It’s all happening this week as an array of income funds join our list of lists of ‘cheap’, ‘expensive’ and biggest falling investment trusts.